<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0603245031
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ZINFORO 600 MG I.V. VIAL
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CEFTAROLINE FOSAMIL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        600
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1897.6
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ACS DOBFAR SPA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ACS DOBFAR SPA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            PFIZER
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01DI02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Zinforo is</strong></p><p>Zinforo is an antibiotic medicine that contains the active substance ceftaroline fosamil. It belongs to a group of medicines called &lsquo;cephalosporin antibiotics.&rsquo;</p><p>&nbsp;</p><p><strong>What Zinforo is used for</strong></p><p>Zinforo is used to treat children (from birth) and adults with:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infections of the skin and the tissues below the skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an infection of the lungs called &lsquo;pneumonia&rsquo;</p><p>&nbsp;</p><p><strong>How Zinforo works</strong></p><p>Zinforo works by killing certain bacteria, which can cause serious infections.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Zinforo:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic to ceftaroline fosamil or any of the other ingredients of this medicine (listed in section&nbsp;6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic to other cephalosporin antibiotics</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have had previous severe allergic reactions to other antibiotics like penicillin or carbapenem.</p><p>&nbsp;</p><p>Do not use Zinforo if any of the above applies to you. If you are not sure, talk to your doctor or nurse before using Zinforo.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or nurse before using Zinforo:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have kidney problems (your doctor may have to prescribe a lower dose)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have ever had fits (seizures or convulsions)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have ever had any non-severe allergic reactions to other antibiotics like penicillin or carbapenem</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have had severe diarrhoea whilst taking antibiotics in the past</p><p>&nbsp;</p><p>You may get another infection caused by another bacteria during or following treatment with Zinforo.</p><p>&nbsp;</p><p>You may develop signs and symptoms of severe skin reactions such as fever, joint pain, skin rash, red scaly rash, skin bumps that contain pus, blisters or peeling of skin, red circular patches often with central blisters on the trunk, ulcers of mouth, throat, nose, genitals and eyes. If this happens talk to your doctor or nurse immediately.</p><p>&nbsp;</p><p><u>Lab Test</u></p><p>You may develop an abnormal lab test (called Coombs test) that looks for certain antibodies which may act against your red blood cells. If the level of your red blood cells fall your doctor may check to see if these antibodies have caused this.</p><p>&nbsp;</p><p>If any of the above apply to you (or you are not sure), talk to your doctor or nurse before using Zinforo.</p><p>&nbsp;</p><p><strong>Other medicines and Zinforo</strong></p><p>Tell your doctor or nurse if you are using, have recently used or might use any other medicines.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>Tell your doctor before using Zinforo if you are pregnant. Do not use this medicine during pregnancy unless your doctor has told you to.</p><p>&nbsp;</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Zinforo may cause side effects such as dizziness. This may impair your ability to drive or operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Zinforo will be given to you by a doctor or nurse.</p><p>&nbsp;</p><p><strong>How much to use</strong></p><p>The usual recommended dose for adults is 600&nbsp;mg every 12&nbsp;hours. Your doctor may increase your dose to 600&nbsp;mg every 8&nbsp;hours for some infections. The usual recommended dose for children depends on the age and weight of the child and is given every 8 or 12&nbsp;hours. It is given as a drip into a vein lasting 5 to 60&nbsp;minutes if you receive the usual dose&nbsp;or 120&nbsp;minutes if you receive an increased dose.</p><p>&nbsp;</p><p>A course of treatment usually lasts for 5 to 14&nbsp;days for skin infections and 5 to 7&nbsp;days for pneumonia.</p><p>&nbsp;</p><p><strong>Patients with kidney problems</strong></p><p>If you have kidney problems your doctor may lower your dose because Zinforo is removed from your body by the kidneys.</p><p>&nbsp;</p><p><strong>If you use more Zinforo than you should</strong></p><p>If you think you have been given too much Zinforo, tell your doctor or nurse straight away.</p><p>&nbsp;</p><p><strong>If you miss a dose of Zinforo</strong></p><p>If you think you have missed a dose, tell your doctor or nurse straight away.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effects may happen with this medicine:</p><p>&nbsp;</p><p><strong>Tell your doctor straight away if you get these symptoms as you may need urgent medical treatment:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sudden swelling of your lips, face, throat or tongue; a severe rash; and, swallowing or breathing problems. These may be signs of a severe allergic reaction (anaphylaxis) and may be life-threatening;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea that becomes severe or does not go away or stool that contains blood or mucus during or after treatment with Zinforo. In this situation, you should not take medicines that stop or slow bowel movement.</p><p>&nbsp;</p><p><strong>Very common (may affect more than 1 in 10 people)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in a blood test called a &lsquo;Coombs test&rsquo; commonly seen in patients receiving this type of antibiotic. This test looks for certain antibodies which may act against your red blood cells.</p><p>&nbsp;</p><p><strong>Common (may affect up to 1 in 10 people)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling dizzy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itching, skin rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea, stomach pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling sick (nausea) or being sick (vomiting)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; More enzymes produced by your liver (as shown in blood tests)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain and irritation of the veins</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Redness, pain or swelling where the injection was given.</p><p>&nbsp;</p><p><strong>Uncommon (may affect up to 1 in 100 people)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anaemia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Raised itchy rash (hives)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An increase in the level of creatinine in your blood. Creatinine shows how well your kidneys are working.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bleeding or bruising more than usual. This may be because the level of platelets in your blood has dropped.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in tests which measure how well your blood clots.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A decrease in the total number of white blood cells, ora certain type of white blood cells in your blood (leucopenia and neutropenia).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in your mental state such as confusion, reduced level of consciousness, abnormal movements or fits (encephalopathy) &ndash; these have occurred in people when the dose they are given is too high, particularly in people with kidney problems.</p><p>&nbsp;</p><p><strong>Rare (may affect up to 1 in 1,000 people)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A significant decrease in the number of certain white blood cells in your blood (agranulocytosis). You may experience fever, flu-like symptoms, sore throat, or any other infection which may be serious.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An increase in the number of certain white blood cells in your blood (eosinophilia).</p><p><strong>&nbsp;</strong></p><p><strong>Not known (frequency cannot be estimated from the available data)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A form of lung disease where eosinophils (a form of white blood cell) appear in the lung in increased numbers (eosinophilic pneumonia).</p><p><strong>&nbsp;</strong></p><p><strong>Sudden chest pain,</strong> which may be a sign of a potentially serious allergic reaction called Kounis syndrome has been noted with other medicines of the same type. If this happens talk to a doctor or nurse immediately.</p><p><strong>&nbsp;</strong></p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>National Pharmacovigilance Center (NPC)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Call center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other</strong><strong> GCC States</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the container. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Dry powder: 36 months.</p><p>Store below 30&deg;C.</p><p>&nbsp;</p><p>Store in the original package in order to protect from light.</p><p>&nbsp;</p><p>Medicines should not be disposed of via wastewater or household waste. The hospital will dispose of any waste materials safely. These measures will help to protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each vial contains 600&nbsp;mg of ceftaroline fosamil.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredient is arginine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	Zinforo is a pale yellowish-white to light yellow powder for concentrate for solution for infusion in a vial. It is available in packs containing 10 vials.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder </strong></p><p>Pfizer Ireland Pharmaceuticals</p><p>Ringaskiddy, Ireland</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>&nbsp;</p><p>ACS Dobfar S.p.A., Milan, Italy</p><p>and</p><p>ACS Dobfar S.p.A., Teramo, Italy</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                February 2024
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما هو زينفورو</strong></p><p dir="RTL">زينفورو هو دواء مضاد حيوي يحتوي على المادة الفعالة سيفتارولين فوساميل. وهو ينتمي إلى مجموعة من الأدوية تسمى &quot;المضادات الحيوية من فئة السيفالوسبورينات&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>وما هي دواعي استعماله</strong></p><p dir="RTL">يُستخدم زينفورو لعلاج الأطفال (من سن الولادة) والبالغين المصابين:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بحالات عدوى في الجلد والأنسجة تحت الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعدوى في الرئتين تسمى &quot;الالتهاب الرئوي&quot;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيفية عمل زينفورو</strong></p><p dir="RTL">يعمل زينفورو عن طريق القضاء على بكتيريا معينة يمكنها أن تسبب حالات عدوى خطيرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>موانع استعمال زينفورو:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بالحساسية تجاه سيفتارولين فوساميل أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم ٦).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بالحساسية تجاه المضادات الحيوية الأخرى من فئة السيفالوسبورينات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد أصبت في السابق بتفاعلات حساسية شديدة تجاه مضادات حيوية أخرى مثل البنسيلين أو كاربابينيم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم زينفورو إذا انطبق عليك أي من الحالات الواردة أعلاه. إذا لم تكن متأكدًا، فتحدث إلى طبيبك أو الممرضة قبل استخدام زينفورو.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الاحتياطات عند استعمال زينفورو </strong></p><p dir="RTL">تحدث إلى طبيبك أو الممرضة قبل استخدام زينفورو:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بمشكلات في الكلى (قد يتعين على طبيبك أن يصف جرعة أقل)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد أصبت من قبل بنوبات (تشنجات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد أصبت من قبل بأي تفاعلات حساسية غير شديدة تجاه مضادات حيوية أخرى مثل البنسيلين أو كاربابينيم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد أصبت بإسهال شديد أثناء تناول المضادات الحيوية في السابق</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تصاب بعدوى أخرى ناتجة عن بكتيريا أخرى أثناء أو بعد العلاج بزينفورو.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تظهر عليك علامات وأعراض لتفاعلات جلدية شديدة مثل الحمى، ألم المفاصل، الطفح الجلدي، طفح جلدي أحمر متقشر، نتوءات جلدية بها قيح أو بثور أو مصحوبة بتقشر في الجلد، بقع دائرية حمراء على الجذع مصحوبة غالبًا ببثور في مركزها، قرح بالفم، والحلق، والأنف، والأعضاء التناسلية والعينين. إذا حدث ذلك، فتحدث مع طبيبك أو الممرضة فورًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الاختبارات المعملية</u></p><p dir="RTL">قد تظهر لديك نتائج غير طبيعية لاختبار معملي (يسمى اختبار كومبس) يبحث عن بعض الأجسام المضادة التي قد تعمل ضد خلايا دمك الحمراء. إذا انخفض مستوى خلايا دمك الحمراء، فقد يتحقق طبيبك لمعرفة ما إذا كانت هذه الأجسام المضادة هي السبب في ذلك الانخفاض أم لا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا انطبق عليك أي من الحالات الواردة أعلاه (أو إذا لم تكن متأكدًا)، فتحدث إلى طبيبك أو الممرضة قبل استخدام زينفورو.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التداخلات الدوائية من أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">أخبر طبيبك أو الممرضة إذا كنت تستخدم أو استخدمت مؤخرًا أو قد تستخدم أي أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">أخبري طبيبكِ قبل استخدام زينفورو إذا كنتِ حاملًا. لا تستخدمي هذا الدواء أثناء الحمل إلا إذا أخبركِ طبيبكِ بهذا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنتِ حاملًا أو ترضعين رضاعة طبيعية أو تعتقدين أنكِ ربما تكونين حاملًا أو كنتِ تخططين للحمل، فاستشيري طبيبكِ قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثير زينفورو على القيادة واستخدام الآلات</strong></p><p dir="RTL">قد يسبب زينفورو آثارًا جانبية مثل الدوار. وقد يسبب هذا خللًا في قدرتك على القيادة أو تشغيل الآلات.</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيتم إعطاؤك زينفورو بواسطة طبيب أو ممرضة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الكمية التي ينبغي استخدامها</strong></p><p dir="RTL">الجرعة المعتادة الموصى بها للبالغين هي ٦٠٠ ملجم كل ١٢ ساعة. يمكن أن يقوم طبيبك بزيادة جرعتك إلى ٦٠٠ ملجم كل ٨ ساعات لعلاج بعض حالات العدوى. تعتمد الجرعة المعتادة الموصى بها للأطفال على عمر ووزن الطفل وتُعطى كل ٨ ساعات أو ١٢ ساعة. يتم إعطاء هذه الجرعة في صورة تنقيط في أحد الأوردة يستمر لفترة تتراوح بين ٥ دقائق و٦٠ دقيقة إذا تلقيت الجرعة المعتادة، أو ١٢٠ دقيقة إذا تلقيت جرعة مرتفعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">عادة ما تستمر دورة العلاج لمدة ٥ إلى ١٤ يومًا لعلاج حالات عدوى الجلد ولمدة ٥ إلى ٧ أيام لعلاج الالتهاب الرئوي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المرضى المصابون بمشكلات في الكلى</strong></p><p dir="RTL">إذا كنت مصابًا بمشكلات في الكلى فقد يقلل طبيبك جرعتك، نظرًا لأنه يتم إخراج زينفورو من جسمك بواسطة الكليتين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة الزائدة من زينفورو</strong></p><p dir="RTL">إذا كنت تعتقد أنه قد تم إعطاؤك جرعة أكبر مما ينبغي من زينفورو، فأخبر طبيبك أو الممرضة على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نسيان تناول جرعة زينفورو</strong></p><p dir="RTL">إذا كنت تعتقد أنه قد فاتتك إحدى الجرعات، فأخبر طبيبك أو الممرضة على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، فاسأل طبيبك أو الممرضة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL">كما هو الحال بالنسبة لجميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، إلا أنها لا تصيب الجميع. قد تحدث الآثار الجانبية التالية عند استخدام هذا الدواء:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخبر طبيبك على الفور إذا أصبت بهذه الأعراض حيث إنك قد تحتاج إلى علاج طبي عاجل:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم مفاجئ في شفتيك، أو وجهك، أو حلقك، أو لسانك؛ وطفح جلدي شديد؛ ومشكلات في البلع أو التنفس. قد تكون هذه علامات أحد تفاعلات الحساسية الشديدة (التأق) وقد تكون مهددة للحياة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال يصبح شديدًا أو لا يزول أو براز يحتوي على دم أو مخاط أثناء أو بعد العلاج بزينفورو. في هذه الحالة، ينبغي ألا تتناول أدوية توقف حركة الأمعاء أو تبطئها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة جدًا (قد تصيب أكثر من شخص واحد من بين كل ١٠ أشخاص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود تغيرات في نتائج فحص دم يُسمى &quot;اختبار كومبس&quot;، تتم ملاحظتها بشكل شائع لدى المرضى الذين يتلقون هذا النوع من المضادات الحيوية. يبحث هذا الاختبار عن بعض الأجسام المضادة التي قد تعمل ضد خلايا دمك الحمراء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة (قد تصيب ما يصل إلى شخص واحد من بين كل ١٠ أشخاص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالدوار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحكة، الطفح الجلدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال، ألم المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور برغبة في التقيؤ (الغثيان) أو التقيؤ بالفعل (القيء)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة نسبة الإنزيمات التي ينتجها كبدك (كما يظهر في نتائج فحوصات الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بألم وتهيج في الأوردة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاحمرار أو الألم أو التورم في موضع إعطاء الحقن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة (قد تصيب ما يصل إلى شخص واحد من بين كل ١٠٠ شخص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقر الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي البارز المصحوب بحكة (الشرى)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى الكرياتينين في دمك. يظهر مستوى الكرياتينين مدى الكفاءة التي تعمل بها كليتاك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النزيف أو التكدم بدرجة أكبر من المعتاد. قد يكون هذا بسبب انخفاض مستوى الصفائح الدموية في دمك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود تغيرات في نتائج الاختبارات التي تقيس قدرة دمك على التخثر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في العدد الكلي لخلايا الدم البيضاء، أو أنواع معينة من خلايا الدم البيضاء في دمك (قلة الكريات البيض وقلة العدلات).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في الحالة العقلية مثل الشعور بالتشوش، انخفاض مستوى الوعي، حركات أو نوبات غير طبيعية (الاعتلال الدماغي) &ndash; قد يُصاب الأشخاص بهذه الأعراض عندما تكون الجرعة التي تُعطى لهم عالية جدًا، وخاصةً لدى الأشخاص الذين يعانون من مشكلات في الكلى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة (قد تصيب ما يصل إلى شخص واحد من بين كل ١٠٠٠ شخص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض بالغ في عدد أنواع معينة من خلايا الدم البيضاء في دمك (ندرة المحببات). قد تصاب بالحمى، أو أعراض شبيهة بالإنفلونزا، أو احتقان الحلق، أو أي عدوى أخرى قد تكون خطيرة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع في عدد أنواع معينة من خلايا الدم البيضاء في دمك (فرط اليوزينيات).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير معروفة (لا يمكن تقييم معدل تكرارها من خلال البيانات المتاحة)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوع من أمراض الرئة تظهر فيه اليوزينيات (أحد أنواع خلايا الدم البيضاء) في الرئة بأعداد متزايدة (الالتهاب الرئوي اليوزيني).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ألم مفاجئ في الصدر،</strong> قد يكون علامة على تفاعل حساسية خطير محتمل يسمى متلازمة كونيس، وقد لوحظ ذلك عند التناول مع أدوية أخرى من نفس النوع. إذا حدث ذلك، فتحدث إلى الطبيب أو الممرضة على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">إذا أصبت بأي آثار جانبية، فتحدث مع طبيبك أو الممرضة. يتضمن هذا أي آثار جانبية محتملة غير مدرجة في هذه النشرة. يمكنك أيضًا الإبلاغ عن الآثار الجانبية مباشرةً عبر نظام الإبلاغ الوطني. بالإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكة العربية السعودية:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>المركز الوطني للتيقظ الدوائي</strong></p><p dir="RTL">o&nbsp; مركز الاتصال: ١٩٩٩٩</p><p dir="RTL">o&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">o&nbsp; الموقع الإلكتروني: https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>دول الخليج الأخرى</strong></p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><em>-&nbsp;&nbsp; </em><em>الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</em></p></td></tr></tbody></table><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&nbsp;</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد مرور تاريخ انتهاء الصلاحية المدون على الحاوية. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في الشهر المذكور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">المسحوق الجاف:&nbsp; ٣٦ شهر.</p><p dir="RTL">قم بتخزينه في درجة حرارة أقل من ٣٠ درجة مئوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قم بتخزينه في عبوته الأصلية لحمايته من الضوء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي عدم التخلص من الأدوية عبر مياه الصرف أو مع المخلفات المنزلية. سوف تتخلص المستشفى من أي مخلفات بشكل آمن. ستساعد هذه الإجراءات في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحتوي كل قارورة على ٦٠٠ ملجم من سيفتارولين فوساميل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكون الآخر هو أرجينين.</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL">زينفورو هو مسحوق يتراوح لونه بين أبيض مائل إلى الأصفر الباهت وبين أصفر فاتح، يتوفر في قارورة لتحضير ركازة مخصصة لإعداد محلول للتسريب. وهو متوفر في عبوات تحتوي على ١٠ قوارير.</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مالك رخصة التسويق</p><p dir="RTL">Pfizer Ireland Pharmaceuticals</p><p dir="RTL">Ringaskiddy, Ireland، أيرلندا</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">جهة التصنيع</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ACS Dobfar S.p.A., Milan, Italy، إيطاليا</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ACS Dobfar S.p.A., Teramo, Italy، إيطاليا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            فبراير/شباط ٢٠٢٤
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Zinforo 600 mg powder for concentrate for solution for infusion


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial contains ceftaroline fosamil acetic acid solvate monohydrate equivalent to 600 mg ceftaroline fosamil.

After reconstitution, 1 mL of the solution contains 30 mg of ceftaroline fosamil.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for concentrate for solution for infusion (powder for concentrate).

A pale yellowish-white to light yellow powder.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Zinforo is indicated for the treatment of the following infections in neonates, infants, children, adolescents and adults(see sections&nbsp;4.4 and&nbsp;5.1):</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Complicated skin and soft tissue infections (cSSTI)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Community-acquired pneumonia (CAP)</p><p>&nbsp;</p><p>Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>The recommended durations of treatment are 5-14&nbsp;days for cSSTI and 5-7&nbsp;days for CAP.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p><strong>Table&nbsp;1&nbsp;&nbsp;&nbsp; Dosage in adults with normal renal function, creatinine clearance (CrCL) &gt;</strong>&nbsp;<strong>50</strong>&nbsp;<strong>mL/min</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p><strong>Indications</strong></p></td><td style="vertical-align:top"><p><strong>Posology (mg/infusion)</strong></p></td><td style="vertical-align:top"><p><strong>Infusion time<sup> </sup>(minutes)/Frequency</strong></p></td></tr></thead><tbody><tr><td><p><u>Standard dose<sup>a</sup></u></p><p><u>&nbsp;</u></p><p>Complicated skin and soft tissue infections (cSSTI)</p><p>&nbsp;</p><p>Community-acquired pneumonia (CAP)</p></td><td rowspan="2"><p>&nbsp;</p><p>600&nbsp;mg</p><p>&nbsp;</p><p>&nbsp;</p></td><td><p>5 &ndash; 60<sup>b</sup>/every 12&nbsp;hours</p></td></tr><tr><td><p><u>High dose<sup>b</sup></u></p><p><u>&nbsp;</u></p><p>cSSTI<sup> </sup>confirmed or suspected to be caused by <em>S. aureus</em> with an MIC&nbsp;=&nbsp;2&nbsp;mg/L or 4&nbsp;mg/L to ceftaroline<sup>c</sup></p></td><td><p>120/every 8&nbsp;hours</p></td></tr><tr><td colspan="3"><p><sup>a</sup>&nbsp;&nbsp; For patients with supranormal renal clearance receiving the standard dose, an infusion time of 60 minutes may be preferable.</p><p><sup>b</sup>&nbsp; Infusion times of less than 60&nbsp;minutes and high dose recommendations are based on pharmacokinetic and pharmacodynamic analyses only. See sections 4.4 and 5.1.</p><p><sup>c&nbsp;&nbsp; </sup>For treatment of <em>S. aureus</em> for which the ceftaroline MIC is &le;&nbsp;1&nbsp;mg/L, the standard dose is recommended.</p><p>&nbsp;</p><p>&nbsp;</p></td></tr><tr><td colspan="3"><p><sup>&nbsp;</sup></p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Table&nbsp;2&nbsp;&nbsp;&nbsp;&nbsp; Dosage in paediatric patients with normal renal function, creatinine clearance </strong><strong>(CrCL) &gt;</strong><strong>&nbsp;</strong><strong>50</strong><strong>&nbsp;</strong><strong>mL/min</strong>*</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p><strong>Indications </strong></p></td><td style="vertical-align:top"><p><strong>Age group</strong></p></td><td style="vertical-align:top"><p><strong>Posology (mg/infusion)</strong></p></td><td style="vertical-align:top"><p><strong>Infusion time<sup> </sup>(minutes)/Frequency</strong></p></td></tr></thead><tbody><tr><td rowspan="4"><p><u>Standard dose<sup>a</sup></u></p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p>Complicated skin and soft tissue infections (cSSTI)</p><p>&nbsp;</p><p>&nbsp;</p><p>Community-acquired pneumonia (CAP)</p></td><td style="vertical-align:top"><p>Adolescents aged from 12 to &lt;&nbsp;18&nbsp;years with bodyweight &ge;&nbsp;33&nbsp;kg</p></td><td><p>600&nbsp;mg</p></td><td><p>5&ndash;60<sup>b</sup>/every 12&nbsp;hours</p></td></tr><tr><td style="vertical-align:top"><p>Adolescents aged from 12&nbsp;years to &lt;&nbsp;18&nbsp;years bodyweight &lt;&nbsp;33&nbsp;kg <strong>and </strong>children &ge;&nbsp;2&nbsp;years to &lt;&nbsp;12&nbsp;years</p></td><td><p>12&nbsp;mg/kg to a maximum of 400&nbsp;mg</p></td><td><p>5&ndash;60<sup>b</sup>/every 8&nbsp;hours</p></td></tr><tr><td style="vertical-align:top"><p>Infants &ge;&nbsp;2&nbsp;months to &lt;&nbsp;2&nbsp;years</p></td><td><p>8&nbsp;mg/kg</p></td><td><p>5&ndash;60<sup>b</sup>/every 8&nbsp;hours</p></td></tr><tr><td style="vertical-align:top"><p>Neonates from birth to &lt;&nbsp;2&nbsp;months<sup>b</sup></p></td><td><p>6 mg/kg</p></td><td><p>60/every 8 hours</p></td></tr><tr><td rowspan="2"><p><u>High dose<sup>b</sup></u></p><p><u>&nbsp;</u></p><p>cSSTI<sup> </sup>confirmed or suspected to be caused by <em>S. aureus</em> with an MIC&nbsp;=&nbsp;2&nbsp;mg/L or 4&nbsp;mg/L to ceftaroline<sup>c</sup></p></td><td style="vertical-align:top"><p>Children and adolescents aged from &ge;&nbsp;2&nbsp;years to &lt;&nbsp;18&nbsp;years</p><p>&nbsp;</p></td><td><p>12&nbsp;mg/kg to a maximum of 600&nbsp;mg</p><p>&nbsp;</p></td><td><p>120/every 8&nbsp;hours</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Infants &ge;&nbsp;2&nbsp;months to &lt;&nbsp;2&nbsp;years</p></td><td><p>10&nbsp;mg/kg</p></td><td><p>120/every 8&nbsp;hours</p></td></tr><tr><td colspan="4"><p><sup>a</sup>&nbsp;&nbsp; For patients with supranormal renal clearance receiving the standard dose, an infusion time of 60 minutes may be preferable.</p><p><sup>b</sup>&nbsp; Infusion times of less than 60&nbsp;minutes, neonatal and high dose recommendations are based on pharmacokinetic and pharmacodynamic analyses only. See sections 4.4 and 5.1.</p><p><sup>c&nbsp;&nbsp; </sup>For treatment of <em>S. aureus</em> for which the ceftaroline MIC is &le;&nbsp;1&nbsp;mg/L, the standard dose is recommended.</p><p>* Calculated using the Schwartz formula (in mL/min/1.73&nbsp;m<sup>2</sup>) for paediatric patients.</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Special populations</u></p><p><em>&nbsp;</em></p><p><em>Elderly</em></p><p>No dosage adjustment is required for the elderly with creatinine clearance values &gt;&nbsp;50&nbsp;mL/min (see section&nbsp;5.2).</p><p><em>&nbsp;</em></p><p><em>Renal impairment</em></p><p>The dose should be adjusted when creatinine clearance (CrCL) is &le;&nbsp;50&nbsp;mL/min, as shown in Tables&nbsp;3&nbsp;and&nbsp;4 (see sections 4.9 and 5.2). The recommended durations of treatment are 5‑14&nbsp;days for cSSTI and 5‑7&nbsp;days for CAP.</p><p>&nbsp;</p><p><strong>Table&nbsp;3&nbsp;&nbsp;&nbsp;&nbsp; Dosage in adults with impaired renal function, creatinine clearance (CrCL) &le;&nbsp;50&nbsp;mL/min</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p><strong>Indications</strong></p></td><td style="vertical-align:top"><p><strong>Creatinine clearance (mL/min)<sup>a</sup></strong></p></td><td style="vertical-align:top"><p><strong>Posology (mg/infusion)</strong></p></td><td style="vertical-align:top"><p><strong>Infusion time<sup> </sup>(minutes)/Frequency</strong></p></td></tr></thead><tbody><tr><td rowspan="3"><p><u>Standard dose</u></p><p><u>&nbsp;</u></p><p>Complicated skin and soft tissue infections(cSSTI)</p><p>&nbsp;</p><p>Community-acquired pneumonia (CAP)</p></td><td><p>&gt;&nbsp;30 to &le;&nbsp;50</p></td><td><p>400&nbsp;mg</p></td><td rowspan="3"><p>5&ndash;60<sup>c</sup>/every 12&nbsp;hours</p></td></tr><tr><td><p>&ge;&nbsp;15 to &le;&nbsp;30</p></td><td><p>300&nbsp;mg</p></td></tr><tr><td style="vertical-align:top"><p>ESRD, including haemodialysis<sup>b</sup></p></td><td style="vertical-align:top"><p>200&nbsp;mg</p></td></tr><tr><td rowspan="3"><p><u>High dose<sup>c</sup></u></p><p>&nbsp;</p><p>cSSTI<sup> </sup>confirmed or suspected to be caused by <em>S.&nbsp;aureus</em> with an MIC&nbsp;=&nbsp;2&nbsp;mg/L or 4&nbsp;mg/L to ceftaroline<sup>d</sup></p></td><td><p>&gt;&nbsp;30 to &le;&nbsp;50</p></td><td><p>400&nbsp;mg</p></td><td rowspan="3"><p>120/every 8&nbsp;hours</p></td></tr><tr><td><p>&ge;&nbsp;15 to &le;&nbsp;30</p></td><td><p>300&nbsp;mg</p></td></tr><tr><td><p>ESRD, including haemodialysis<sup>b</sup></p></td><td><p>200&nbsp;mg</p></td></tr><tr><td colspan="4"><p><sup>a</sup>&nbsp;&nbsp; Calculated using the Cockcroft-Gault formula for adults. Dose is based on CrCL. CrCL should be closely monitored and the dose adjusted according to changing renal function.</p><p><sup>b</sup>&nbsp; Ceftaroline is haemodialyzable; thus Zinforo should be administered after haemodialysis on haemodialysis days.</p><p><sup>c&nbsp;&nbsp; </sup>Infusion times of less than 60&nbsp;minutes and high dose recommendations are based on pharmacokinetic and pharmacodynamic analyses only. See sections 4.4 and 5.1.</p><p><sup>d&nbsp;&nbsp; </sup>For treatment of <em>S.&nbsp;aureus</em> for which the ceftaroline MIC is &le;&nbsp;1&nbsp;mg/L, the standard dose is recommended.</p><p>&nbsp;</p></td></tr></tbody></table><p>Dose recommendations for neonates, infants and children and adolescents are based on pharmacokinetic (PK) modelling.</p><p>&nbsp;</p><p>There is insufficient information to recommend dosage adjustments in adolescents aged from 12 to &lt;&nbsp;18&nbsp;years with bodyweight &lt;&nbsp;33&nbsp;kg and in children aged from 2 to 12&nbsp;years with End-stage renal disease (ESRD).</p><p>&nbsp;</p><p>There is insufficient information to recommend dosage adjustments in paediatric patients &lt;&nbsp;2&nbsp;years with moderate or severe renal impairment or ESRD.</p><p><strong>&nbsp;</strong></p><p><strong>Table&nbsp;4&nbsp;&nbsp;&nbsp;&nbsp; Dosage in paediatric patients with impaired renal function, creatinine clearance (CrCL) &le;&nbsp;50&nbsp;mL/min</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:99%"><thead><tr><td style="vertical-align:top"><p><strong>Indications</strong></p></td><td style="vertical-align:top"><p><strong>Age group</strong></p></td><td style="vertical-align:top"><p><strong>Creatinine clearance (mL/min)<sup>a</sup></strong></p><p><strong><sup>&nbsp;</sup></strong></p></td><td style="vertical-align:top"><p><strong>Posology</strong></p><p><strong>(mg/infusion)</strong></p></td><td style="vertical-align:top"><p><strong>Infusion time<sup> </sup>(minutes)/Frequency</strong></p></td></tr></thead><tbody><tr><td rowspan="5"><p><u>Standard dose</u><sup> </sup></p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p>Complicated skin and soft tissue infections (cSSTI)</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Community-acquired pneumonia (CAP)</p></td><td rowspan="3"><p>Adolescents aged from 12&nbsp;to &lt;&nbsp;18&nbsp;years with bodyweight &ge;&nbsp;33&nbsp;kg</p></td><td><p>&gt;&nbsp;30 to &le;&nbsp;50</p></td><td><p>400&nbsp;mg</p></td><td rowspan="3"><p>5&ndash;60<sup>c</sup>/every 12&nbsp;hours</p></td></tr><tr><td><p>&ge;&nbsp;15 to &le;&nbsp;30</p></td><td><p>300&nbsp;mg</p></td></tr><tr><td><p>ESRD, including haemodialysis<sup>b</sup></p></td><td><p>200&nbsp;mg</p></td></tr><tr><td rowspan="2"><p>Adolescents aged from 12&nbsp;years to &lt;&nbsp;18&nbsp;years bodyweight &lt;&nbsp;33&nbsp;kg <strong>and </strong>children &ge;&nbsp;2&nbsp;years to &lt;&nbsp;12&nbsp;years</p></td><td><p>&gt;&nbsp;30 to &le;&nbsp;50</p></td><td><p>8&nbsp;mg/kg to a maximum of 300&nbsp;mg</p></td><td rowspan="2"><p>5&ndash;60<sup>c</sup>/every 8&nbsp;hours</p></td></tr><tr><td><p>&ge;&nbsp;15 to &le;&nbsp;30</p></td><td><p>6&nbsp;mg/kg to a maximum of 200&nbsp;mg</p></td></tr><tr><td rowspan="2"><p><u>High dose<sup>c</sup></u></p><p>&nbsp;</p><p>cSSTI<sup> </sup>confirmed or suspected to be caused by <em>S. aureus</em> with an MIC&nbsp;=&nbsp;2&nbsp;mg/L or 4&nbsp;mg/L to ceftaroline<sup>d</sup></p></td><td rowspan="2"><p>Children and adolescents aged from &ge;2&nbsp;years to &lt;&nbsp;18&nbsp;years</p></td><td><p>&gt;&nbsp;30 to &le;&nbsp;50</p></td><td><p>10&nbsp;mg/kg to a maximum of 400&nbsp;mg</p></td><td rowspan="2"><p>120/every 8&nbsp;hours</p></td></tr><tr><td><p>&ge;&nbsp;15 to &le;&nbsp;30</p><p>&nbsp;</p></td><td><p>8&nbsp;mg/kg to a maximum of 300&nbsp;mg</p><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><sup>a</sup>&nbsp;&nbsp; Calculated using the Schwartz formula for paediatric patients (in mL/min/1.73&nbsp;m<sup>2)</sup>. Dose is based on CrCL. CrCL should be closely monitored and the dose adjusted according to changing renal function.</p><p><sup>b </sup>&nbsp; Ceftaroline is haemodialyzable; thus Zinforo should be administered after haemodialysis on haemodialysis days.</p><p><sup>c&nbsp;&nbsp; </sup>Infusion times of less than 60&nbsp;minutes and high dose recommendations are based on pharmacokinetic and pharmacodynamic analyses only. See sections 4.4 and 5.1.</p><p><sup>d&nbsp;&nbsp; </sup>For treatment of <em>S. aureus</em> for which the ceftaroline MIC is &le;&nbsp;1&nbsp;mg/L, the standard dose is recommended.</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>No dosage adjustment is considered necessary in patients with hepatic impairment (see section&nbsp;5.2).</p><p><u>&nbsp;</u></p><p><u>Method of administration</u></p><p>Intravenous use. Zinforo is administered by intravenous infusion over 5 to 60&nbsp;minutes for standard dose or 120&nbsp;minutes for high dose (for cSSTI caused by <em>S. aureus </em>with MIC of 2&nbsp;or 4&nbsp;mg/L to ceftaroline) in infusion volumes of 50&nbsp;mL, 100&nbsp;mL or 250&nbsp;mL (see section&nbsp;6.6). Infusion related reactions (such as phlebitis) can be managed by prolonging the infusion duration.</p><p>&nbsp;</p><p>Infusion volumes for paediatric patients will vary according to the weight of the child. The infusion solution concentration during preparation and administration should not exceed 12&nbsp;mg/mL ceftaroline fosamil.</p><p>&nbsp;</p><p>For instructions on reconstitution and dilution of the medicinal product before administration, see section&nbsp;6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Hypersensitivity to the cephalosporin class of antibacterials.
Immediate and severe hypersensitivity (e.g. anaphylactic reaction) to any other type of beta-lactam antibacterial agent (e.g. penicillins or carbapenems).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p><u>Hypersensitivity reactions</u></p><p>Serious and occasionally fatal hypersensitivity reactions are possible (see sections&nbsp;4.3&nbsp;and&nbsp;4.8).</p><p>&nbsp;</p><p>Severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalised exanthematous pustulosis (AGEP) have been reported in association with beta‑lactam antibiotics (including cephalosporins) treatment.</p><p>&nbsp;</p><p>Patients who have a history of hypersensitivity to cephalosporins, penicillins or other beta-lactam antibacterials may also be hypersensitive to ceftaroline fosamil. Ceftaroline should be used with caution in patients with a history of non-severe hypersensitivity reactions to any other beta-lactam antibiotics (e.g. penicillins or carbapenems). If a severe allergic reaction or SCAR occurs during treatment with Zinforo, the medicinal product should be discontinued and appropriate measures taken.</p><p>&nbsp;</p><p>With other beta-lactam antibiotics there have been reports of hypersensitivity reactions which progressed to Kounis syndrome (acute allergic coronary arteriospasm that can result in myocardial infarction, see section 4.8).</p><p>&nbsp;</p><p><em><u>Clostridium difficile</u></em><u>-associated diarrhoea </u></p><p>Antibacterial-associated colitis and pseudomembranous colitis have been reported with ceftaroline fosamil and may range in severity from mild to life threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhoea during or subsequent to the administration of ceftaroline fosamil (see section&nbsp;4.8). In such circumstance, the discontinuation of therapy with ceftaroline fosamil and the use of supportive measures together with the administration of specific treatment for <em>Clostridium difficile</em> should be considered.</p><p>&nbsp;</p><p><u>Non-susceptible organisms</u></p><p>Superinfections may occur during or following treatment with Zinforo.</p><p>&nbsp;</p><p><u>Patients with pre-existing seizure disorder </u></p><p>Seizures have occurred in toxicology studies at 7‑25&nbsp;times human ceftaroline C<sub>max</sub> levels (see section&nbsp;5.3). Clinical study experience with ceftaroline fosamil in patients with pre-existing seizure disorders is very limited. Therefore, Zinforo should be used with caution in this patient population.</p><p>&nbsp;</p><p><u>Direct antiglobulin test (Coombs test) seroconversion and potential risk of haemolytic anaemia</u></p><p>The development of a positive direct antiglobulin test (DAGT) may occur during treatment with cephalosporins. The incidence of DAGT seroconversion in patients receiving ceftaroline fosamil was 11.2% in the five pooled pivotal studies with administration every 12&nbsp;hours (600&nbsp;mg administered over 60&nbsp;minutes every 12&nbsp;hours) and 32.3% in a study in patients receiving ceftaroline fosamil every 8&nbsp;hours (600&nbsp;mg administered over 120&nbsp;minutes every 8&nbsp;hours), (see section&nbsp;4.8). In clinical studies there was no evidence of haemolysis in patients who developed a positive DAGT on treatment. However, the possibility that haemolytic anaemia may occur in association with cephalosporins including Zinforo treatment cannot be ruled out. Patients experiencing anaemia during or after treatment with Zinforo should be investigated for this possibility.</p><p><u>&nbsp;</u></p><p><u>Limitations of the clinical data</u></p><p>There is no experience with ceftaroline in the treatment of CAP in the following patient groups: the immunocompromised, patients with severe sepsis/septic shock, severe underlying lung disease (e.g. cystic fibrosis, see section 5.2), those with PORT Risk Class V, and/or CAP requiring ventilation at presentation, CAP due to methicillin-resistant <em>S. aureus</em> or patients requiring intensive care. Caution is advised when treating such patients.</p><p>&nbsp;</p><p>There is no experience with ceftaroline in the treatment of cSSTI in the following patient groups: the immunocompromised, patients with severe sepsis/septic shock, necrotizing fasciitis, perirectal abscess and patients with third degree and extensive burns. There is limited experience in treating patients with diabetic foot infections. Caution is advised when treating such patients.</p><p>&nbsp;</p><p>There are limited clinical trial data on the use of ceftaroline to treat cSSTI caused by <em>S. aureus</em> with an MIC of &gt;&nbsp;1&nbsp;mg/L. The recommended dosages of Zinforo shown in Tables&nbsp;1 to 4 for the treatment of cSSTI caused by <em>S. aureus </em>with ceftaroline MIC of 2 or 4&nbsp;mg/L are based on pharmacokinetic-pharmacodynamic modelling and simulation (see sections&nbsp;4.2 and&nbsp;5.1). Zinforo should not be used to treat cSSTI due to <em>S. aureus</em> for which the ceftaroline MIC is &gt;&nbsp;4&nbsp;mg/L.</p><p>&nbsp;</p><p>The recommended dosage of Zinforo shown in Table 2 for paediatric patients &lt;&nbsp;2 months of age are based on pharmacokinetic-pharmacodynamic modelling and simulation.</p><p>&nbsp;</p><p>Infusion times of less than 60&nbsp;minutes are based on pharmacokinetic and pharmacodynamic analyses only.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No clinical drug-drug interaction studies have been conducted with ceftaroline fosamil.</p><p>&nbsp;</p><p>The interaction potential of ceftaroline or ceftaroline fosamil on medicinal products metabolised by CYP450 enzymes is expected to be low since they are not inhibitors nor inducers of CYP450 enzymes <em>in vitro</em>. Ceftaroline or ceftaroline fosamil are not metabolised by CYP450 enzymes <em>in vitro</em>, therefore co-administered CYP450 inducers or inhibitors are unlikely to influence the pharmacokinetics of ceftaroline.</p><p>&nbsp;</p><p>Ceftaroline is neither a substrate, nor an inhibitor of renal uptake transporters (OCT2, OAT1, and OAT3) <em>in vitro</em>. Therefore, interactions of ceftaroline with medicinal products that are substrates or inhibitors (e.g. probenecid) of these transporters would not be expected.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>As with adults, the interaction potential is expected to be low in paediatrics.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are no or limited amount of data from the use of ceftaroline fosamil in pregnant women. Animal studies conducted in rat and rabbit do not indicate harmful effects with respect to reproductive toxicity at exposures similar to therapeutic concentrations. Following administration throughout pregnancy and lactation in the rat, there was no effect on pup birth weight or growth, although minor changes in foetal weight and delayed ossification of the interparietal bone were observed when ceftaroline fosamil was administered during organogenesis (see section&nbsp;5.3).</p><p>&nbsp;</p><p>As a precautionary measure, it is preferable to avoid the use of Zinforo during pregnancy unless the clinical condition of the woman requires treatment with an antibiotic with Zinforo&rsquo;s antibacterial profile.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>It is unknown whether ceftaroline fosamil or ceftaroline is excreted in human milk. A risk to the newborns/infants cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Zinforo therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>The effects of ceftaroline fosamil on fertility on humans have not been studied. Animal studies with ceftaroline fosamil do not indicate harmful effects with respect to fertility (see section&nbsp;5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Undesirable effects e.g. dizziness may occur and this may have an effect on the ability to drive and use of machines (see section&nbsp;4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The most common adverse reactions occurring in &ge;&nbsp;3% of approximately 3242 patients treated with Zinforo in clinical studies were diarrhoea, headache, nausea, and pruritus, and were generally mild or moderate in severity. <em>Clostridium difficile</em>-associated disease (CDAD) and severe hypersensitivity reactions may also occur.</p><p>&nbsp;</p><p>A greater incidence of rash in Asian patients (see below) and a greater incidence of DAGT seroconversion (see section&nbsp;4.4) were observed in a study of adult patients with cSSTI conducted with Zinforo 600&nbsp;mg administered over 120 minutes every 8 hours.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>The following adverse reactions have been identified during clinical trials and post-marketing experience with Zinforo. Adverse reactions are classified according to System Organ Class and frequency. Frequency categories are derived according to the following conventions: very common (&ge;&nbsp;1/10), common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10), uncommon (&ge;&nbsp;1/1,000 to &lt;&nbsp;1/100), rare (&ge;&nbsp;1/10,000 to &lt;&nbsp;1/1,000), not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p><strong>Table 5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Frequency of adverse reactions by system organ class from clinical trials and post-marketing experience</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Very common</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td><td style="vertical-align:top"><p><strong>Not known</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><em>Clostridium difficile</em> colitis (see section&nbsp;4.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><em>&nbsp;</em></p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaemia, leucopenia, neutropenia<sup>*</sup>, thrombocytopenia, prothrombin time (PT) prolonged, activated partial thromboplastin time (aPTT) prolonged, international normalized ratio (INR) increased</p></td><td style="vertical-align:top"><p>Agranulocytosis<sup>*</sup>, eosinophilia<sup>*</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rash, pruritus</p></td><td style="vertical-align:top"><p>Anaphylaxis, hypersensitivity (e.g. urticaria, lip and face swelling) (see sections&nbsp;4.3 and&nbsp;4.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Headache, dizziness</p></td><td style="vertical-align:top"><p>Encephalopathy<sup>*,+</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Phlebitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Eosinophilic pneumonia<sup>*</sup></p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Diarrhoea, nausea, vomiting, abdominal pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Increased transaminases</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Blood creatinine increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pyrexia, infusion site reactions (erythema, phlebitis, pain)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Coombs Direct Test Positive (see section&nbsp;4.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>* Adverse Drug Reaction (ADR) identified post-marketing.</p><p>+ Risk of encephalopathy is higher in patients with renal impairment in whom the dose of ceftaroline has not been appropriately reduced (see sections 4.2 and 4.9).</p><p><u>&nbsp;</u></p><p><u>Description of selected adverse reactions</u></p><p><u>&nbsp;</u></p><p><em>Severe Cutaneous Adverse Reactions</em></p><p>SCARs (Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms, acute generalised exanthematous pustulosis) have been reported with beta-lactam antibiotics, including cephalosporins (see section 4.4).</p><p>&nbsp;</p><p><em>Kounis Syndrome</em></p><p>Acute coronary syndrome associated with an allergic reaction (Kounis syndrome) has been reported with other beta-lactam antibiotics.</p><p>&nbsp;</p><p><em>Rash</em></p><p>Rash was observed at a common frequency in both the pooled Phase III studies in cSSTI with administration of Zinforo every 12&nbsp;hours (600&nbsp;mg administered over 60&nbsp;minutes every 12&nbsp;hours) and the study in cSSTI with administration every 8&nbsp;hours (600&nbsp;mg administered over 120&nbsp;minutes every 8&nbsp;hours). However, the frequency of rash in the subgroup of Asian patients receiving Zinforo every 8&nbsp;hours was very common (18.5%).</p><p><strong><em>&nbsp;</em></strong></p><p><u>Paediatric population</u></p><p>The safety assessment in paediatric patients is based on the safety data from 2 trials in which 227&nbsp;patients aged from 2 months to 17 years with cSSTI or CAP received Zinforo. Overall, the safety profile in these 227 patients was similar to that observed in the adult population.</p><p>&nbsp;</p><p>In addition, the safety assessment in neonates is based on the safety data from 2 trials in which 34&nbsp;patients (age range from birth to less than 60 days) received Zinforo; 23 of these patients received only a single dose of Zinforo. Overall, the adverse events reported in these studies were consistent with the known safety profile for Zinforo.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system.</p><p><strong>&nbsp;</strong></p><p><strong>To Report side effects</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>National Pharmacovigilance Center (NPC)</strong></p><p>&nbsp;</p><p>Call center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other</strong><strong> GCC States</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Limited data in patients receiving higher than recommended Zinforo dosages show similar adverse reactions as observed in the patients receiving recommended dosages. Treatment of overdose should follow standard medical practice.</p><p>&nbsp;</p><p><u>Patients with renal impairment</u></p><p><u>&nbsp;</u></p><p>Relative overdosing could occur in patients with moderate renal impairment. Neurological sequelae, including encephalopathy, have been noted in cases where beta-lactam antibiotics (including cephalosporins) have been given to patients with impaired renal function without reducing the dose (see section 4.2).</p><p>&nbsp;</p><p>Ceftaroline can be removed by haemodialysis; over a 4&nbsp;hour dialysis period, approximately 74% of a given dose was recovered in the dialysate.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antibacterials for systemic use, other cephalosporins and penems, ATC&nbsp;code: J01DI02</p><p>&nbsp;</p><p>The active moiety after Zinforo administration is ceftaroline.</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Ceftaroline is a cephalosporin antibacterial with <em>in vitro</em> activity against Gram-positive and ‑negative bacteria.&nbsp; The bactericidal action of ceftaroline is mediated through binding to essential penicillin-binding proteins (PBPs).&nbsp;Biochemical studies have shown that ceftaroline has high affinity for PBP2a of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA) and PBP2x of penicillin non-susceptible <em>Streptococcus pneumoniae</em> (PNSP). As a result, minimum inhibitory concentrations (MICs) of ceftaroline against a proportion of these organisms tested fall into the susceptible range (see Resistance section below).</p><p>&nbsp;</p><p><u>Resistance</u></p><p>Ceftaroline is not active against strains of <em>Enterobacterales</em> producing extended-spectrum beta-lactamases (ESBLs) from the TEM, SHV or CTX-M families, serine carbapenemases (such as KPC), class B metallo-beta-lactamases or class C (AmpC) cephalosporinases. Organisms that express these enzymes and which are therefore resistant to ceftaroline occur at very variable rates between countries and between healthcare facilities within countries. If ceftaroline is commenced before susceptibility test results are available then local information on the risk of encountering organisms that express these enzymes should be taken into consideration. Resistance may also be mediated by bacterial impermeability or drug efflux pump mechanisms. One or more of these mechanisms may co-exist in a single bacterial isolate.</p><p>&nbsp;</p><p><u>Interaction with other antibacterial agents</u></p><p><em>In vitro</em> studies have not demonstrated any antagonism between ceftaroline in combination with other commonly used antibacterial agents (e.g. amikacin, azithromycin, aztreonam, daptomycin, levofloxacin, linezolid, meropenem, tigecycline, and vancomycin).</p><p>&nbsp;</p><p><u>Susceptibility testing breakpoints</u></p><p>MIC (minimum inhibitory concentration) interpretive criteria for susceptibility testing have been established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) for ceftaroline fosamil and are listed here: https://www.ema.europa.eu/documents/other/minimum-inhibitory-concentration-mic-breakpoints_en.xlsx</p><p><u>Pharmacokinetic/pharmacodynamic relationship</u></p><p>As with other beta-lactam antimicrobial agents, the percent time above the minimum inhibitory concentration (MIC) of the infecting organism over the dosing interval (%T&nbsp;&gt;&nbsp;MIC) has been shown to be the parameter that best correlates with the efficacy of ceftaroline.</p><p>&nbsp;</p><p><u>Clinical efficacy against specific pathogens</u></p><p>Efficacy has been demonstrated in clinical studies against the pathogens listed under each indication that were susceptible to ceftaroline <em>in vitro</em>.</p><p>&nbsp;</p><p><em>Complicated skin and soft tissue infections</em></p><p><em><u>Gram-positive micro-organisms</u></em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Staphylococcus aureus</em> (including methicillin-resistant strains)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Streptococcus pyogenes </em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Streptococcus agalactiae </em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Streptococcus anginosus</em> group (includes <em>S. anginosus</em>, <em>S. intermedius</em>, and <em>S. constellatus</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Streptococcus dysgalactiae </em></p><p>&nbsp;</p><p><em><u>Gram-negative micro-organisms</u></em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Escherichia coli</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Klebsiella pneumoniae </em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Klebsiella oxytoca </em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Morganella morganii </em></p><p>&nbsp;</p><p><em>Community-acquired pneumonia</em></p><p>No cases of CAP due to MRSA were enrolled into the studies. The available clinical data cannot substantiate efficacy against penicillin non-susceptible strains of <em>S. pneumoniae</em>.</p><p>&nbsp;</p><p><em><u>Gram-positive micro-organisms</u></em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Streptococcus pneumoniae</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Staphylococcus aureus</em> (methicillin-susceptible strains only)</p><p>&nbsp;</p><p><em><u>Gram-negative micro-organisms</u></em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Escherichia coli</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Haemophilus influenzae </em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Haemophilus parainfluenzae </em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Klebsiella pneumoniae</em></p><p><u>&nbsp;</u></p><p><u>Antibacterial activity against other relevant pathogens</u></p><p><u>&nbsp;</u></p><p>Clinical efficacy has not been established against the following pathogens although <em>in vitro</em> studies suggest that they would be susceptible to ceftaroline in the absence of acquired mechanisms of resistance:</p><p>&nbsp;</p><p><em>Anaerobic micro-organisms</em></p><p><em><u>Gram-positive micro-organisms</u></em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Peptostreptococcus</em> spp.</p><p>&nbsp;</p><p><em><u>Gram-negative micro-organisms</u></em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Fusobacterium</em> spp.</p><p>&nbsp;</p><p><em>In vitro </em>data indicate that the following species are not susceptible to ceftaroline:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Chlamydophila</em> spp.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Legionella</em> spp.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Mycoplasma</em> spp.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Proteus </em>spp.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Pseudomonas aeruginosa</em></p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The C<sub>max</sub> and AUC of ceftaroline increase approximately in proportion to dose within the single dose range of 50&nbsp;to&nbsp;1000&nbsp;mg. No appreciable accumulation of ceftaroline is observed following multiple intravenous infusions of 600&nbsp;mg every 8 or 12&nbsp;hours in healthy adults with CrCL &gt;&nbsp;50&nbsp;mL/min.</p><p><strong>&nbsp;</strong></p><p><u>Distribution</u></p><p><u>&nbsp;</u></p><p>The plasma protein binding of ceftaroline is low (approximately 20%) and ceftaroline is not distributed into erythrocytes. The median steady-state volume of distribution of ceftaroline in healthy adult males following a single 600&nbsp;mg intravenous dose of radiolabelled ceftaroline fosamil was 20.3&nbsp;l, similar to the volume of extracellular fluid.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>&nbsp;</p><p>Ceftaroline fosamil (prodrug) is converted into the active ceftaroline in plasma by phosphatase enzymes and concentrations of the prodrug are measurable in plasma primarily during intravenous infusion. Hydrolysis of the beta-lactam ring of ceftaroline occurs to form the microbiologically inactive, open-ring metabolite, ceftaroline M-1. The mean plasma ceftaroline M-1 to ceftaroline AUC ratio following a single 600&nbsp;mg intravenous infusion of ceftaroline fosamil in healthy subjects is approximately 20‑30%.</p><p>&nbsp;</p><p>In pooled human liver microsomes, metabolic turnover was low for ceftaroline, indicating that ceftaroline is not metabolised by hepatic CYP450 enzymes.</p><p>&nbsp;</p><p><u>Elimination</u></p><p><u>&nbsp;</u></p><p>Ceftaroline is primarily eliminated by the kidneys. Renal clearance of ceftaroline is approximately equal, or slightly lower than the glomerular filtration rate in the kidney, and <em>in vitro</em> transporter studies indicate that active secretion does not contribute to the renal elimination of ceftaroline.</p><p>&nbsp;</p><p>The mean terminal elimination half-life of ceftaroline in healthy adults is approximately 2.5&nbsp;hours.</p><p>&nbsp;</p><p>Following the administration of a single 600&nbsp;mg intravenous dose of radiolabelled ceftaroline fosamil to healthy male adults, approximately 88% of radioactivity was recovered in urine and 6% in faeces.</p><p>&nbsp;</p><p><u>Special populations</u></p><p><u>&nbsp;</u></p><p><em>Renal impairment</em></p><p>Dosage adjustments are required in adults, adolescents and children with CrCL &le;&nbsp;50&nbsp;mL/min (see section&nbsp;4.2).</p><p>&nbsp;</p><p>There is insufficient information to recommend dosage adjustments in adolescents with ESRD aged from 12 to &lt;&nbsp;18&nbsp;years and with bodyweight &lt;&nbsp;33&nbsp;kg and in children with ESRD aged from 2 to &lt;&nbsp;12&nbsp;years. There is insufficient information to recommend dosage adjustments in paediatric patients aged &lt;&nbsp;2&nbsp;years with moderate or severe renal impairment or ESRD.</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>The pharmacokinetics of ceftaroline in patients with hepatic impairment has not been established. As ceftaroline does not appear to undergo significant hepatic metabolism, the systemic clearance of ceftaroline is not expected to be significantly affected by hepatic impairment. Therefore, no dosage adjustment is recommended for patients with hepatic impairment.</p><p>&nbsp;</p><p><em>Elderly</em></p><p>Following administration of a single 600&nbsp;mg intravenous dose of ceftaroline fosamil, the pharmacokinetics of ceftaroline were similar between healthy elderly subjects (&ge;&nbsp;65&nbsp;years of age), and healthy young adult subjects (18‑45&nbsp;years of age). There was a 33% increase in AUC<sub>0-&infin;</sub> in the elderly that was mainly attributable to age-related changes in renal function. Zinforo dose adjustment is not required in elderly patients with creatinine clearance above 50&nbsp;mL/min.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>Dose adjustments are required for neonates, infants, children and adolescents with bodyweight &lt;&nbsp;33&nbsp;kg (see section&nbsp;4.2).</p><p>&nbsp;</p><p><em>Patients with cystic fibrosis</em></p><p>Cystic fibrosis patients were excluded from CAP clinical trials.</p><p>&nbsp;</p><p>Some case reports and published studies suggest the need for a higher dose of ceftaroline fosamil in cystic fibrosis patients due to possibility of altered ceftaroline pharmacokinetics leading to sub‑therapeutic levels. Results from a population pharmacokinetic study, based on data pooled from various studies, overall showed no significant, clinically relevant differences in ceftaroline pharmacokinetic parameters in cystic fibrosis patients (age 6 years and above). Ceftaroline clearance was similar between cystic fibrosis patients and patients with CAP or cSSTI while ceftaroline central volume was similar to healthy subjects.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The C<sub>max</sub> and AUC of ceftaroline increase approximately in proportion to dose within the single dose range of 50&nbsp;to&nbsp;1000&nbsp;mg. No appreciable accumulation of ceftaroline is observed following multiple intravenous infusions of 600&nbsp;mg every 8 or 12&nbsp;hours in healthy adults with CrCL &gt;&nbsp;50&nbsp;mL/min.</p><p><strong>&nbsp;</strong></p><p><u>Distribution</u></p><p><u>&nbsp;</u></p><p>The plasma protein binding of ceftaroline is low (approximately 20%) and ceftaroline is not distributed into erythrocytes. The median steady-state volume of distribution of ceftaroline in healthy adult males following a single 600&nbsp;mg intravenous dose of radiolabelled ceftaroline fosamil was 20.3&nbsp;l, similar to the volume of extracellular fluid.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>&nbsp;</p><p>Ceftaroline fosamil (prodrug) is converted into the active ceftaroline in plasma by phosphatase enzymes and concentrations of the prodrug are measurable in plasma primarily during intravenous infusion. Hydrolysis of the beta-lactam ring of ceftaroline occurs to form the microbiologically inactive, open-ring metabolite, ceftaroline M-1. The mean plasma ceftaroline M-1 to ceftaroline AUC ratio following a single 600&nbsp;mg intravenous infusion of ceftaroline fosamil in healthy subjects is approximately 20‑30%.</p><p>&nbsp;</p><p>In pooled human liver microsomes, metabolic turnover was low for ceftaroline, indicating that ceftaroline is not metabolised by hepatic CYP450 enzymes.</p><p>&nbsp;</p><p><u>Elimination</u></p><p><u>&nbsp;</u></p><p>Ceftaroline is primarily eliminated by the kidneys. Renal clearance of ceftaroline is approximately equal, or slightly lower than the glomerular filtration rate in the kidney, and <em>in vitro</em> transporter studies indicate that active secretion does not contribute to the renal elimination of ceftaroline.</p><p>&nbsp;</p><p>The mean terminal elimination half-life of ceftaroline in healthy adults is approximately 2.5&nbsp;hours.</p><p>&nbsp;</p><p>Following the administration of a single 600&nbsp;mg intravenous dose of radiolabelled ceftaroline fosamil to healthy male adults, approximately 88% of radioactivity was recovered in urine and 6% in faeces.</p><p>&nbsp;</p><p><u>Special populations</u></p><p><u>&nbsp;</u></p><p><em>Renal impairment</em></p><p>Dosage adjustments are required in adults, adolescents and children with CrCL &le;&nbsp;50&nbsp;mL/min (see section&nbsp;4.2).</p><p>&nbsp;</p><p>There is insufficient information to recommend dosage adjustments in adolescents with ESRD aged from 12 to &lt;&nbsp;18&nbsp;years and with bodyweight &lt;&nbsp;33&nbsp;kg and in children with ESRD aged from 2 to &lt;&nbsp;12&nbsp;years. There is insufficient information to recommend dosage adjustments in paediatric patients aged &lt;&nbsp;2&nbsp;years with moderate or severe renal impairment or ESRD.</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>The pharmacokinetics of ceftaroline in patients with hepatic impairment has not been established. As ceftaroline does not appear to undergo significant hepatic metabolism, the systemic clearance of ceftaroline is not expected to be significantly affected by hepatic impairment. Therefore, no dosage adjustment is recommended for patients with hepatic impairment.</p><p>&nbsp;</p><p><em>Elderly</em></p><p>Following administration of a single 600&nbsp;mg intravenous dose of ceftaroline fosamil, the pharmacokinetics of ceftaroline were similar between healthy elderly subjects (&ge;&nbsp;65&nbsp;years of age), and healthy young adult subjects (18‑45&nbsp;years of age). There was a 33% increase in AUC<sub>0-&infin;</sub> in the elderly that was mainly attributable to age-related changes in renal function. Zinforo dose adjustment is not required in elderly patients with creatinine clearance above 50&nbsp;mL/min.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>Dose adjustments are required for neonates, infants, children and adolescents with bodyweight &lt;&nbsp;33&nbsp;kg (see section&nbsp;4.2).</p><p>&nbsp;</p><p><em>Patients with cystic fibrosis</em></p><p>Cystic fibrosis patients were excluded from CAP clinical trials.</p><p>&nbsp;</p><p>Some case reports and published studies suggest the need for a higher dose of ceftaroline fosamil in cystic fibrosis patients due to possibility of altered ceftaroline pharmacokinetics leading to sub‑therapeutic levels. Results from a population pharmacokinetic study, based on data pooled from various studies, overall showed no significant, clinically relevant differences in ceftaroline pharmacokinetic parameters in cystic fibrosis patients (age 6 years and above). Ceftaroline clearance was similar between cystic fibrosis patients and patients with CAP or cSSTI while ceftaroline central volume was similar to healthy subjects.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Arginine</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products except those mentioned in section&nbsp;6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	Do not use this medicine after the expiry date which is stated on the carton label after EXP:. The expiry date refers to the last day of that month.
	
Dry powder: 3 years

After reconstitution:
The reconstituted vial should be diluted immediately.

After dilution:
Once the intravenous solution is prepared with diluents listed in section 6.6 it should be administered within 6 hours of preparation. The chemical and physical in-use stability has been demonstrated for up to 12 hours at 2 8 °C. Once removed from refrigeration to room temperature, the diluted product must be used within 6 hours.

From a microbiological point of view, the medicinal product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 12 hours at 2 to 8ºC, unless reconstitution/dilution has taken place in controlled and validated aseptic conditions.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&nbsp;&deg;C.</p><p>Store in the original package in order to protect from light.</p><p>For storage conditions after reconstitution of the medicinal product, see section&nbsp;6.3.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>20&nbsp;mL glass vial (Type 1) closed with a rubber (halobutyl) stopper and aluminium seal with flip-off cap.</p><p>&nbsp;</p><p>The medicinal product is supplied in packs of 10&nbsp;vials.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The powder must be reconstituted with water for injections and the resulting concentrate must then be immediately diluted prior to use. The reconstituted solution is a pale yellow solution that is free of any particles.</p><p>&nbsp;</p><p>Standard aseptic techniques should be used for solution preparation and administration.</p><p>&nbsp;</p><p>Zinforo powder should be reconstituted with 20&nbsp;mL of sterile water for injections. The resulting solution should be shaken prior to being transferred to an infusion bag or bottle containing either sodium chloride 9&nbsp;mg/mL (0.9%) solution for injection, dextrose 50&nbsp;mg/mL (5%) solution for injection, sodium chloride 4.5&nbsp;mg/mL and dextrose 25&nbsp;mg/mL solution for injection (0.45% sodium chloride and 2.5% dextrose) or Lactated Ringer&rsquo;s solution. A 250&nbsp;mL, 100&nbsp;mL or 50&nbsp;mL infusion bag can be used to prepare the infusion, based on the patient&rsquo;s volume requirements. The total time interval between starting reconstitution and completing preparation of the intravenous infusion should not exceed 30&nbsp;minutes.</p><p>&nbsp;</p><p>Infusion volumes for paediatric patients will vary according to the weight of the child. The infusion solution concentration during preparation and administration should not exceed 12&nbsp;mg/mL ceftaroline fosamil.</p><p>&nbsp;</p><p>Each vial is for single use only.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MARKETING AUTHORISATION HOLDER

Pfizer Ireland Pharmaceuticals, Ringaskiddy, Ireland

MANUFACTURER:

Manufactured by ACS Dobfar S.p.A., Milan, Italy and ACS Dobfar S.p.A, Teramo, Italy

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                February 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>